Your browser doesn't support javascript.
loading
Rationale and design of the pullback pressure gradient (PPG) global registry.
Munhoz, Daniel; Collet, Carlos; Mizukami, Takuya; Yong, Andy; Leone, Antonio Maria; Eftekhari, Ashkan; Ko, Brian; da Costa, Bruno R; Berry, Colin; Collison, Damien; Perera, Divaka; Christiansen, Evald Høj; Rivero, Fernando; Zimmermann, Frederik M; Ando, Hirohiko; Matsuo, Hitoshi; Nakayama, Masafumi; Escaned, Javier; Sonck, Jeroen; Sakai, Koshiro; Adjedj, Julien; Desta, Liyew; van Nunen, Lokien X; West, Nick E J; Fournier, Stephane; Storozhenko, Tatyana; Amano, Tetsuya; Engstrøm, Thomas; Johnson, Thomas; Shinke, Toshiro; Biscaglia, Simone; Fearon, William F; Ali, Ziad; De Bruyne, Bernard; Johnson, Nils P.
Afiliação
  • Munhoz D; Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium; Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy.
  • Collet C; Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium.
  • Mizukami T; Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium; Division of Clinical Pharmacology, Department of Pharmacology, Showa University, Tokyo, Japan.
  • Yong A; Concord Repatriation General Hospital, University of Sydney, New South Wales, Australia.
  • Leone AM; Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University School of Medicine, Rome, Italy; Center of Excellence in Cardiovascular Diagnostics and Therapeutic, Ospedale Fabenefratelli Isola Tiberina Gemelli Isola, Rome, Italy.
  • Eftekhari A; Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.
  • Ko B; Monash Cardiovascular Research Centre, Monash University and Monash Heart, Monash Health, Clayton, Victoria, Australia.
  • da Costa BR; Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, England; Clinical Epidemiology and Health Care Research, Institute of Health Policy and Management Evaluation (IHPME), University of Toronto, Toronto, Ontorio,
  • Berry C; School Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
  • Collison D; School Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
  • Perera D; School of Cardiovascular Medicine and Sciences, St Thomas' Hospital Campus, King's College London, London, UK.
  • Christiansen EH; Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
  • Rivero F; Cardiac Department, Hospital Universitario de La Princesa, Madrid, Spain.
  • Zimmermann FM; Department of Cardiology, Catharina Hospital Eindhoven, Eindhoven, The Netherlands.
  • Ando H; Department of Cardiology, Aichi Medical University, Aichi, Japan.
  • Matsuo H; Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan.
  • Nakayama M; Department of Cardiology, Tokyo D Tower Hospital, Tokyo, Japan.
  • Escaned J; Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos and Complutense University, Madrid, Spain.
  • Sonck J; Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium.
  • Sakai K; Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium; Department of Medicine, Division of Cardiology, Showa University School of Medicine, Tokyo, Japan.
  • Adjedj J; Department of Cardiology, Arnault Tzanck Institute Saint Laurent du Var, France.
  • Desta L; Department of Cardiology, Karolinska University Hospital, Solna, Stockholm, Sweden.
  • van Nunen LX; Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • West NEJ; Abbott Vascular, Santa Clara, CA.
  • Fournier S; Department of Cardiology, University Hospital of Lausanne, Lausanne, Switzerland.
  • Storozhenko T; Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium; Department of Prevention and Treatment of Emergency Conditions, L.T. Malaya Therapy National Institute NAMSU, Kharkiv, Ukraine.
  • Amano T; Department of Cardiology, Aichi Medical University, Aichi, Japan.
  • Engstrøm T; Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Johnson T; University Hospitals Bristol & Weston NHS Foundation Trust, Bristol, United Kingdom.
  • Shinke T; Department of Medicine, Division of Cardiology, Showa University School of Medicine, Tokyo, Japan.
  • Biscaglia S; Cardiology Unit, Azienda Ospedaliera Universitaria di Ferrara, Ferrara, Italy.
  • Fearon WF; Division of Cardiovascular Medicine and Stanford Cardiovascular Institute, Stanford University School of Medicine and VA Palo Alto Health Care System, Palo Alto, CA.
  • Ali Z; St Francis Hospital and Heart Center, Roslyn, NY.
  • De Bruyne B; Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium; Department of Cardiology, University Hospital of Lausanne, Lausanne, Switzerland.
  • Johnson NP; Weatherhead PET Center, Division of Cardiology, Department of Medicine, McGovern Medical School at UTHealth and Memorial Hermann Hospital, Houston, TX. Electronic address: nils.johnson@uth.tmc.edu.
Am Heart J ; 265: 170-179, 2023 Nov.
Article em En | MEDLINE | ID: mdl-37611857
ABSTRACT

INTRODUCTION:

Diffuse disease has been identified as one of the main reasons leading to low post-PCI fractional flow reserve (FFR) and residual angina after PCI. Coronary pressure pullbacks allow for the evaluation of hemodynamic coronary artery disease (CAD) patterns. The pullback pressure gradient (PPG) is a novel metric that quantifies the distribution and magnitude of pressure losses along the coronary artery in a focal-to-diffuse continuum.

AIM:

The primary objective is to determine the predictive capacity of the PPG for post-PCI FFR.

METHODS:

This prospective, large-scale, controlled, investigator-initiated, multicenter study is enrolling patients with at least 1 lesion in a major epicardial vessel with a distal FFR ≤ 0.80 intended to be treated by PCI. The study will include 982 subjects. A standardized physiological assessment will be performed pre-PCI, including the online calculation of PPG from FFR pullbacks performed manually. PPG quantifies the CAD pattern by combining several parameters from the FFR pullback curve. Post-PCI physiology will be recorded using a standardized protocol with FFR pullbacks. We hypothesize that PPG will predict optimal PCI results (post-PCI FFR ≥ 0.88) with an area under the ROC curve (AUC) ≥ 0.80. Secondary objectives include patient-reported and clinical outcomes in patients with focal vs. diffuse CAD defined by the PPG. Clinical follow-up will be collected for up to 36 months, and an independent clinical event committee will adjudicate events.

RESULTS:

Recruitment is ongoing and is expected to be completed in the second half of 2023.

CONCLUSION:

This international, large-scale, prospective study with pre-specified powered hypotheses will determine the ability of the preprocedural PPG index to predict optimal revascularization assessed by post-PCI FFR. In addition, it will evaluate the impact of PPG on treatment decisions and the predictive performance of PPG for angina relief and clinical outcomes.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Am Heart J Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Am Heart J Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália